Association of anti-heparin platelet factor 4 antibody levels and thrombosis in pediatric intensive care patients without thrombocytopenia

Blood Coagulation and Fibrinolysis

Volumn 14, Issue 1, 2003, Pages 113-116

  Risch, Lorenz ^a   Fischer, Joachim E ^b   Schmugge, Markus ^c   Huber, Andreas R ^a  

^a CANTONAL HOSPITAL AARAU   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Antibodies; Catheterization; Children; Heparin; Intensive care; Platelet factor 4; Risk factors; Thrombocytopenia; Thrombosis

Indexed keywords

HEPARIN; THROMBOCYTE ANTIBODY; THROMBOCYTE FACTOR 4;

ANTIBODY DETECTION; ARTICLE; CHILD; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INTENSIVE CARE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOCYTOPENIA; THROMBOSIS;

AUTOANTIBODIES; CASE-CONTROL STUDIES; CATHETERIZATION; HEPARIN; HUMANS; INFANT; INFANT, NEWBORN; INTENSIVE CARE; PLATELET COUNT; PLATELET FACTOR 4; THROMBOCYTOPENIA; THROMBOSIS;

EID: 12244264189     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200301000-00020     Document Type: Article

References (26)

1. Warkentin TE. Heparin-induced thrombocytopenia: a ten year retrospective. Annu Rev Med 1999; 50:129-147.
2. Ranze O, Ranze P, Magnani HN, Greinacher A. Heparin-induced thrombocytopenia in pediatric patients - a review of the literature and a new case treated with danaparoid sodium. Eur J Pediatr 1999; 158 (suppl 3):130-133.
3. Severin T, Sutor AH. Heparin-induced thrombocytopenia in pediatrics. Semin Thromb Hemost 2001; 27:293-299.
4. Schmugge M, Risch L, Huber AR, Benn A, Fischer JE. Heparin-induced thrombocytopenia-associated thrombosis in pediatric intensive care patients. Pediatrics 2002; 109:e10.
5. Heeger PS, Backstrom JR. Heparin flushes and thrombocytopenia [Letter]. Ann Intern Med 1986; 105:143.
6. Laster JL, Nichols WK, Silver D. Thrombocytopenia associated with heparin-coated catheters in patients with heparin associated antiplatelet antibodies. Arch Intern Med 1989; 149:2285-2287.
7. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002; 346:995-1008.
8. Amiral J, Meyer D. Heparin-dependent antigens in heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, (editors): Heparin-induced thrombocytopenia, 2nd edition. New York: Marcel Dekker; 2001. pp. 137-148.
9. Visentin GP, Bacsi SG, Aster RH. Molecular immunopathogenesis of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, (editors): Heparin-induced thrombocytopenia, 2nd edition. New York: Marcel Dekker; 2001. pp. 149-165.
10. Denomme GA. The platelet Fc receptor in heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, (editors): Heparin-induced thrombocytopenia, 2nd edition. New York: Marcel Dekker; 2001. pp. 189-214.
11. Pouplard C, Iochmann S, Renard B, Herault O, Colombat P, Amiral J, Gruel Y. Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia. Blood 2001; 97:3300-3302.
12. Arepally GM, Poncz M, Cines DB. Immune vascular injury in heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, (editors): Heparin-induced thrombocytopenia, 2nd edition. New York: Marcel Dekker; 2001. pp. 215-230.
13. Blank M, Shoenfeld Y, Tavor S, Praprotnik S, Boffa MC, Weksler B, et al. Anti-platelet factor 4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells. Int Immunol 2002; 14:121-129.
14. Warkentin TE, Sheppard JA, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000; 96:1703-1708.
15. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332:1330-1335.
16. Kappers-Klunne MC, Boon DM, Hop WC. Michiels JJ, Stibbe J, van der Zwaan C, et al. Heparin-induced thrombocytopenia and thrombosis: a prospective analysis of the incidence in patients with heart and cerebrovascular diseases. Br J Haematol 1997; 96:442-446.
17. Amiral J, Peynaud-Debayle E, Wolf M, Bridey F, Vissac AM, Meyer D. Generation of antibodies to heparin-PF4 complexes without thrombocytopenia in patients treated with unfractionated or low-molecular-weight heparin. Am J Hematol 1996; 52:90-95.
18. Lockitch G, Halstead AC, Ouigley G, MacCallum C. Age- and sex-specific pediatric reference intervals: study design and methods illustrated by measurement of serum proteins with the Behring LN Nephelometer. Clin Chem 1988; 34:1618-1621.
19. Greinacher A, Amiral J, Dummel V, Visaac A, Kiefel V, Mueller-Eckhardt C. Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay. Transfusion 1994; 34:381-385.
20. Warkentin TE. Heparin-induced skin lesions. Br J Haematol 1996; 92:494-497.
21. Hach-Wunderle V, Kainer K, Salzmann G, Muller-Berghaus G, Potzsch B. Heparin-related thrombosis despite normal platelet counts in vascular surgery. Am J Surg 1997; 173:117-119.
22. Risch L, Pihan H, Zeller C, Huber AR. ET gets HIT - thrombocytotic heparin-induced thrombocytopenia (HIT) in a patient with essential thrombocythemia (ET). Blood Coagul Fibrinolysis 2000; 11:663-667.
23. Sutor AH. Thrombocytosis. In: Lilleyman J, Hann I, Blanchette V, (editors): Pediatric hematology, 2nd edition. London: Churchill Livingstone; 2000. pp. 455-464.
24. Van Ommen CH, Heijboer H, Buller HR, Hirasing RA, Heijmans HS, Peters M. Venous thromboembolism in childhood: a prospective two-year registry in The Netherlands. J Pediatr 2001; 139:676-681.
25. Opatrny L, Warner M. Malignancy associated with thrombosis in heparin-induced thrombocytopenia [abstract]. Blood 2001; 98 (suppl 1):34a.
26. Warkentin TE, Hong AP. Frequency of upper limb deep venous thrombosis (UL-DVT) in relation to central venous catheter (CVC) use in patients with heparin-induced thrombocytopenia (HIT): evidence for interaction of systemic (HIT) and local (CVC) prothrombotic risk factors [abstract]. Blood 1998; 92 (suppl 1):500a-501a.